Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.49 |
| ▸ | TLR8 | Q9NR97 | 11/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30583350 | 1.00 | TLR7 (0.49) | TLR7TLR8NUDT1 | |
| SCHEMBL30583535 | 1.00 | TLR7 (0.49) | TLR7TLR8NUDT1 | |
| SCHEMBL30583358 | 0.95 | TLR7 (0.49) | TLR7TLR8NUDT1 | |
| SCHEMBL30583430 | 0.94 | TLR7 (0.47) | TLR7TLR8NUDT1 | |
| SCHEMBL30583365 | 0.91 | TLR7 (0.53) | TLR7TLR8NUDT1 | |
| SCHEMBL30583603 | 0.90 | TLR7 (0.45) | TLR7TLR8 | |
| SCHEMBL30583254 | 0.89 | TLR7 (0.47) | TLR7TLR8NUDT1 | |
| SCHEMBL30583520 | 0.89 | TLR7 (0.46) | TLR7TLR8NUDT1 | |
| SCHEMBL30583306 | 0.88 | TLR7 (0.49) | TLR7TLR8NUDT1 | |
| SCHEMBL30583348 | 0.85 | TLR7 (0.49) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325687-A1 | CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST | MABSOFT THERAPEUTICS SHANGHAI CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| EP-4508061-A1 | CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST | Mabsoft Therapeutics (Shanghai) Co., Ltd. (CN) | 2025-02-19 | — | — | EP | disclosed |
| CN-119365479-A | Conjugates comprising Toll-like receptor agonists | 慕宝盛科生物医药(上海)有限公司 | 2025-01-24 | — | — | CN | disclosed |
| WO-2023198195-A1 | CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST | MABSOFT THERAPEUTICS (SHANGHAI) CO., LTD. (CN) | 2023-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325687-A1 | CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST | TLR3, TLR7, TLR8 | TLR7 2/4885TLR8 3/4885NUDT1 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.